Gastric cancer: Advances in adjuvant and adjunct therapy

Current Treatment Options in Oncology

Volumn 4, Issue 5, 2003, Pages 413-419

  Higuchi, Katsuhiko ^b   Phan, Alexandria ^b   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Advanced Gastric Cancer; Clin Oncol; Curative Resection; Gastric Cancer; Gastric Carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GASTRECTOMY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142151380     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0042-7     Document Type: Article

References (43)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287–1289. DOI: 10.1001/jama.265.10.1287
2. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5–26. This paper contains the most current statistics for cancers. DOI: 10.3322/canjclin.53.1.5
3. Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr: Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978, 41:941–947. DOI: 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M
4. Wanebo HJ, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993, 218:583–592. DOI: 10.1097/00000658-199311000-00002
5. Heberer G, Teichmann RK, Kramling HJ, Gunther B: Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg 1988, 12:374–381. DOI: 10.1007/BF01655678
6. Allum WH, Powell DJ, McConkey CC, Fielding JW: Gastric cancer: a 25-year review. Br J Surg 1989, 76:535–540. DOI: 10.1002/bjs.1800760604
7. Fujii M, Sasaki J, Nakajima T: State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 1999, 2:151–157. This is a comprehensive review of the current treatment of gastric cancer with a hint of Japanese influence. DOI: 10.1007/s101200050039
8. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345:745–748. DOI: 10.1016/S0140-6736(95)90637-1
9. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ: Extended lymph node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 1999, 340:908–914. This is a Western study assessing whether extended lymph node dissection improves survival. DOI: 10.1056/NEJM199903253401202
10. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: long- term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79:1522–1530. This is another important study assessing whether extended lymph node dissection improves survival. DOI: 10.1038/sj.bjc.6690243
11. MacDonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725–730. This is a sentinel trial changing the current standard practice of adjuvant care in resected gastric cancer in North America. DOI: 10.1056/NEJMoa010187
12. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11:1441–1447.
13. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999, 35:1059–1064. A comprehensive meta-analysis of adjuvant therapy after curative resection of gastric cancer. DOI: 10.1016/S0959-8049(99)00076-3
14. Landry J, Tepper JE, Wood WC, et al.: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990, 19:1357–1362.
15. Kasakura Y, Phan A, Ajani J: Adjuvant therapy for resected gastric carcinoma. Surg Oncol Clin N Am 2002, 11:431–444. This is a comprehensive review of adjuvant therapy for resected gastric cancer from 1990 to 2002. DOI: 10.1016/S1055-3207(02)00009-1
16. Shimada K, Ajani JA: Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of Western and Oriental trials. Cancer 1999, 86:1657–1668. This is a comprehensive review of adjuvant therapy for gastric cancer. DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1657::AID-CNCR6>3.0.CO;2-J
17. Use of thio-TEPA as an adjuvant to the surgical management of carcinoma of the stomach. Veterans Administration Surgical Oncology Study Group. Cancer 1965, 18:291-297.
18. Longmire W, Kuzma J, Dixon W: The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg Oncol 1968, 167:293–312.
19. Coombes RC, Schein PS, Chilvers CE, et al.: A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990, 8:1362–1369.
20. Hallissey MT, Dunn JA, Ward LC, Allum WH: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994, 343:1309–1312. DOI: 10.1016/S0140-6736(94)92464-3
21. MacDonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin- C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 1995, 2:488–494. DOI: 10.1007/BF02307081
22. Lise M, Nitti D, Marchet A, et al.: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995, 13:2757–2763.
23. Allum WH, Hallissey MT, Kelly KA: Adjuvant chemotherapy in operable gastric cancer. 5-year follow-up of first British Stomach Cancer Group trial. Lancet 1989, 1:571–574. DOI: 10.1016/S0140-6736(89)91607-3
24. Carrato A, Diaz-Rubio E, Medrano J: Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C (MMC) and tegafur plus uracil (UFT), starting within the first week after surgery, for gastric adenocarcinoma [abstract]. Proc Am Soc Clin Oncol 1995, 14:A468.
25. Nakajima T, Nashimoto A, Kitamura M, et al.: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999, 354:273–277. DOI: 10.1016/S0140-6736(99)01048-X
26. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000, 58:191–197. S-1 will probably be an important emergent cancer therapy in gastric cancer with a high response rate as a single agent, which was demonstrated in this study. DOI: 10.1159/000012099
27. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982, 49:1116-1122.
28. Higgins GA, Amadeo JH, Smith DE, et al.: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma: a Veterans Administration Surgical Oncology Group report. Cancer 1983, 52:1105–1112. DOI: 10.1002/1097-0142(19830915)52:6<1105::AID-CNCR2820520629>3.0.CO;2-Z
29. Engstrom PF, Lavin PT, Douglass HO, Brunner KW: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985, 55:1868–1873. DOI: 10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B
30. Krook JE, O'Connell MJ, Wieand HS, et al.: A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991, 67:2454–2458. DOI: 10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2
31. Neri B, de Leonardis V, Romano S, et al.: Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996, 73:549–552.
32. Grau JJ, Estape J, Fuster J, et al.: Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998, 16:1036–1039.
33. Takiguchi N, Fujimoto S, Koda K: Postoperative adjuvant chemotherapy is effective in gastric cancer with serosal invasion: multivariate analysis for a randomized controlled trial (doxifluridine vs 5-fluorouracil) [abstract]. Proc Am Soc Clin Oncol 2002:A640. This article describes the possible use of a new approach to treating gastric cancer.
34. Saji S, Toge T, Kurosu Y, et al.: Interim report of JFMC study no. 23: phase III randomized clinical trial on the effectiveness of low-dose cisplatin plus 5-FU as a postoperative adjuvant chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho 2002, 29:2499–2507. This article describes the possible use of a new approach to treating gastric cancer.
35. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000, 11:837–843. This is an interesting article that is compared to MacDonald et al. [11] regarding the role of adjuvant chemotherapy after curative resection for gastric cancer. This is a meta-analysis of all of the randomized trials involving adjuvant therapy in resected gastric cancer. DOI: 10.1023/A:1008377101672
36. Schiessel R, Funovics J, Schick B, et al.: Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial. Acta Med Austriaca 1989, 16:68–69.
37. Sautner T, Hofbauer F, Depisch D, et al.: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994, 12:970–974.
38. Rosen HR, Jatzko G, Repse S, et al.: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998, 16:2733–2738.
39. Yu W, Whang I, Suh I, et al.: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998, 228:347–354. DOI: 10.1097/00000658-199809000-00007
40. Kramling HJ, Wilkowski R, Duhmke E, et al.: Adjuvant intraoperative radiotherapy of stomach carcinoma. Langenbecks Arch Chir Suppl Kongressbd 1996, 113:211–213.
41. Dent DM, Werner ID, Novis B, et al.: Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979, 44:385–391. DOI: 10.1002/1097-0142(197908)44:2<385::AID-CNCR2820440203>3.0.CO;2-8
42. Moertel CG, Childs DS, O'Fallon JR, et al.: Combined 5- fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984, 2:1249–1254.
43. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638–646. This paper may be of interest for further study regarding preoperative therapy in gastric cancer. DOI: 10.1056/NEJMoa010580